相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immunotherapy for Esophageal Cancer: State-of-the Art in 2021
Hugo Teixeira Farinha et al.
CANCERS (2022)
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Ronan J. Kelly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors
Kiyotaka Yoh et al.
LUNG CANCER (2021)
Prognostic Function of Programmed Cell Death-Ligand 1 in Esophageal Squamous Cell Carcinoma Patients Without Preoperative Therapy: A Systematic Review and Meta-Analysis
Hongxia Cui et al.
FRONTIERS IN ONCOLOGY (2021)
Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect
Jiyun Lee et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma
Sha Zhou et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
Clinical Significance of Programmed Death Ligand-1 Expression in Esophageal Squamous Cell Carcinoma
Nozomi Ito et al.
JOURNAL OF SURGICAL RESEARCH (2020)
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Immunosuppressive Phenotype of Esophagus Tumors Stroma
Olga V. Kovaleva et al.
ANALYTICAL CELLULAR PATHOLOGY (2020)
The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer
Tseng-Cheng Chen et al.
ORAL ONCOLOGY (2020)
PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population
Lulu Rong et al.
DIAGNOSTIC PATHOLOGY (2019)
Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma
Sehhoon Park et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato et al.
LANCET ONCOLOGY (2019)
High PD-L1 expression is associated with a favorable prognosis in patients with esophageal squamous cell carcinoma undergoing postoperative adjuvant radiotherapy
Chenxue Jiang et al.
ONCOLOGY LETTERS (2019)
Semi-quantitative Determination of Protein Expression Using Immunohistochemistry Staining and Analysis: An Integrated Protocol
Alexandra R. Crowe et al.
BIO-PROTOCOL (2019)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis
Wei Guo et al.
Oncotarget (2018)
PD-L1 Expression On tumor Cells Was Associated With Unfavorable Prognosis In Esophageal Squamous Cell Carcinoma
Qiao Wang et al.
JOURNAL OF CANCER (2018)
Immunotherapy for esophageal squamous cell carcinoma : a review
Kosaku Mimura et al.
FUKUSHIMA JOURNAL OF MEDICAL SCIENCE (2018)
Concurrent neoadjuvant chemoradiotherapy could improve survival outcomes for patients with esophageal cancer: a meta-analysis based on random clinical trials
Baoxing Liu et al.
ONCOTARGET (2017)
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer
David L. Rimm et al.
JAMA ONCOLOGY (2017)
Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy
Koji Tanaka et al.
CANCER SCIENCE (2016)
Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer
S. H. Lim et al.
EUROPEAN JOURNAL OF CANCER (2016)
Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
Kaiyan Chen et al.
ONCOTARGET (2016)
CD8+/FOXP3+ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer
Yingming Zhu et al.
ONCOTARGET (2016)
Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis
Hai-Xia Qu et al.
JOURNAL OF THORACIC DISEASE (2016)
PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells
Kathleen M. Mahoney et al.
CANCER IMMUNOLOGY RESEARCH (2015)
分享论文
